Cure & Advancements/August 14, 2025/2 min read

New Roadmap Aims to Speed Beta Cell Replacement Therapies Closer to Patients

Researchers at Breakthrough T1D have published guidelines designed to help move beta cell replacement therapies from the lab into clinical practice faster. The roadmap addresses how to design trials and navigate regulatory pathways for these cell-based treatments.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

Beta cell replacement therapies have shown they can restore insulin production and achieve insulin independence in some people with Type 1 diabetes
Current beta cell therapies are only available to a small group of people with severe, hard-to-manage blood sugar swings and require strong immune-suppressing medicines
A new paper outlines a framework for designing clinical trials that could accelerate approval and access to next-generation beta cell therapies
The guidelines emphasize broadening who can benefit from these treatments, not just those with the most severe cases

A Framework for Moving Cell Therapies Forward

Breakthrough T1D, a major research and advocacy organization, published a paper in the journal Diabetes that serves as a roadmap for developing beta cell replacement therapies. The guidelines, authored by Breakthrough T1D leaders including Chief Scientific Officer Sanjoy Dutta, Ph.D., and other experts in the field, are designed to help researchers and companies speed the development, approval, and availability of these cell-based treatments.

The paper is titled "Future Directions and Clinical Trial Considerations for Novel Islet β-Cell Replacement Therapies for Type 1 Diabetes" and provides practical guidance that the entire Type 1 diabetes research community can use to design more efficient clinical trials.

What Beta Cell Therapies Can Do

Decades of research have shown that replacing damaged or destroyed beta cells—the insulin-producing cells affected by Type 1 diabetes—can be effective. In some cases, people who have received beta cell replacement therapies have achieved insulin independence, meaning they no longer needed daily insulin injections.

However, current beta cell replacement therapies come with significant limitations. They are available only to people with Type 1 diabetes who have severe, unstable blood sugar management and frequent dangerous low blood sugar episodes. Additionally, people receiving these therapies must take strong medicines that broadly suppress the immune system to prevent the body from rejecting the transplanted cells.

Expanding Access and Reducing Burden

The new roadmap recognizes that the daily burden of managing Type 1 diabetes is substantial for everyone living with the condition—not just those with the most severe cases. The paper emphasizes the need for innovative clinical trial design that could expand eligibility beyond the current narrow group of patients.

By outlining clear pathways for designing trials and navigating regulatory approval, the guidelines aim to help bring next-generation beta cell replacement therapies to more people with Type 1 diabetes sooner. This could eventually allow more patients to benefit from treatments that restore their body's ability to produce insulin.

Evidence label

Origin: prnewswire.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.